Perceptions and Intention to Get Vaccinated against Mpox among the LGBTIQ+ Community during the 2022 Outbreak : A Cross-Sectional Study in Peru

Vaccination against mpox can control the outbreak by targeting high-risk groups such as the LGBTIQ+ community. The aim of the study was to evaluate the perceptions and intentions to get vaccinated against mpox among the LGBTIQ+ community in Peru. We conducted a cross-sectional study from 1 November 2022 to 17 January 2023 in Peru. We included individuals over 18 years old, belonging to the LGBTIQ+ community, and residing in the departments of Lima and Callao. To evaluate the factors associated with the intention to be vaccinated, we used Poisson regression with robust variance to create a multivariate model. The study comprised 373 individuals who self-identified as members of the LGBTIQ+ community. The participants had a mean age of 31 years (SD ± 9), with 85.0% males and 75.3% reporting to be homosexual men. The majority (88.5%) expressed their intention to receive the vaccine against mpox. Believing that the vaccine is safe was associated with a higher intention to be vaccinated (aPR: 1.24; 95% CI: 1.02 to 1.50; p = 0.028). Our study population showed a high level of mpox vaccination intent. Educational campaigns reinforcing the concept of vaccine safety should be conducted to increase the intention and possibly the vaccination rate in the LGBTIQ+ community.

Medienart:

E-Artikel

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

Zur Gesamtaufnahme - volume:11

Enthalten in:

Vaccines - 11(2023), 5 vom: 21. Mai

Sprache:

Englisch

Beteiligte Personen:

Araoz-Salinas, Julieta M [VerfasserIn]
Ortiz-Saavedra, Brando [VerfasserIn]
Ponce-Rosas, Linda [VerfasserIn]
Soriano-Moreno, David R [VerfasserIn]
Soriano-Moreno, Anderson N [VerfasserIn]
Alave, Jorge [VerfasserIn]
Gonzales-Zamora, Jose A [VerfasserIn]

Links:

Volltext

Themen:

Bisexuality
Homosexuality
Intention
Journal Article
Monkeypox
Perception
Peru
Public health
Vaccination

Anmerkungen:

Date Revised 29.05.2023

published: Electronic

Citation Status PubMed-not-MEDLINE

doi:

10.3390/vaccines11051008

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM357453395